546 Bibliografia [1] Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th ed. Cham (CH): Springer; 2019. [2] Passweg JR, Baldomero H, Chabannon C. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant 2021 Jul;56(7):1651-1664. [3] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. [4] Fianchi L, Criscuolo M, Fabiani E, Falconi G, Maraglino AME, Voso MT, Pagano L. Therapy-related myeloid neoplasms: clinical perspectives. Onco Targets Ther. 2018 Sep 17;11:5909-5915. doi: 10.2147/OTT.S101333. eCollection 2018. [5] Akhtari M, et al. Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplanta- tion in lymphoma patients. Cancer Biol Ther. 2013;14(12):1077–88. [6] Yamasaki S, Suzuki R, Hatano K, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. Bone Marrow Transplant. 2017;52(7): 969–976. [7] Seshadri T, et al. Incidence and risk factors for second cancers after autologous hematopoietic cell transplan- tation for aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(3):380– 6. [8] Laurenti L, et al. Secondary myelodysplastic syndromes following peripheral blood stem cell transplantation: morphological, cytogenetic and clonality evaluation and the limitation of FAB criteria. Bone Marrow Transplant. 2000;26(2):241–2. [9] Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000;95(11):3273–9. [10] Engel N, Rovo A, Badoglio M, Labopn M, Basak W G, Beguin Y. European experience and risk factor analysis of donor cell derived leukaemia following haematopoietic cell transplantation. Leukemia. 2018. [11] Danylesko I, Shimoni A. Second Malignancies after Hematopoietic Stem Cell Transplantation. Curr Treat Options Oncol. 2018 Feb 8;19(2):9. [12] Tichelli A, Beohou E, Labopin M, Socié G, Rovó A, Badoglio M. Transplant Complications Working Party of the EBMT. Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients. JAMA Oncol. 2019 Feb 1;5(2):229-235. [13] Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009 Jan 29;113(5):1175-83. [14] Fianchi L, Pagano L, Piciocchi A, et al. Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am J Hematol. 2015;90(5):E80–E85. [15] Pedersen-Bjergaard J, Pedersen M, Myhre J, Geisler C. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia. 1997 Oct;11(10):1654–60. [16] Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(1):9–16. . [17] Armenian SH, Sun CL, Kawashima T, Arora M, Leisenring W, Sklar CA. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood. 2011 Aug 4;118(5):1413-20. [18] Friedman DL, Rovo A, Leisenring W et al; FHCRC; EBMT-Late Effect Working Party. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood. 2008 Jan 15;111(2):939-44. [19] Leone G, Fianchi L, Pagano L, Voso MT. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact. 2010;184:39–45 [20] Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011 Jan 6;117(1):316-22. [21] Shimoni A, Shem-Tov N, Chetrit A et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced. Leukemia. 2013 Apr;27(4):829-35. [22] Sacchi S, Marcheselli L, Bari A et al. Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year -up study. Haematologica. 2008;93(3):398–404. [23] Baker KS, Leisenring MW, Goodman JP, Ermoian PR, Flowers ME, Schoch G. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood (2019) 133 (26): 2790–2799. [24] Sala-Torra O, Hanna C, Loken MR et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 May;12(5):511-7. [25] Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011; 17:771–89. [26] Curtis RE, Metayer C, Rizzo JD, Socié G, Sobocinski KA, Flowers ME. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005 May 15;105(10):3802-11. [27] Peffault de Latour R, Lévy V, et al L. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004 Mar 1;103(5):1618-24. [28] Cohen A, Rovelli A, Merlo DF, van Lint MT, Lanino E, Brester. Risk for secondary thyroid carcinoma after hematopoietic stemcell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007 Jun 10;25(17):2449-54. [29] Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Non-melanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006 Mar 1;24(7):1119-26. [30] Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Mar;47(3):337-41
RkJQdWJsaXNoZXIy ODUzNzk5